Studies on platelet function in patients with prostatic cancer. Preliminary report.

Area of Science:

• Hematology
• Oncology
• Biochemistry

Background:

• Thromboembolic events are a concern in advanced prostatic cancer.
• Platelet function is a potential indicator of thrombotic risk.
• Benign prostatic hypertrophy (BPH) serves as a relevant control group due to similar demographics.

Purpose of the Study:

• To evaluate platelet function as an index of thromboembolic tendency in advanced prostate cancer.
• To compare platelet parameters between patients with prostate cancer and BPH.
• To investigate the role of platelet serotonin and specific intraplatelet proteins.

Main Methods:

• Assessed platelet aggregation, platelet serotonin, plasma serotonin, beta-thromboglobulin (beta-TG), and platelet factor 4 (PF4).
• Compared measurements between untreated advanced prostate cancer patients and age-matched BPH patients.
• Included comparisons with healthy individuals for beta-TG levels.

Main Results:

• Platelet aggregations were elevated in both prostate cancer and BPH groups, with no significant difference between them.
• Platelet serotonin levels were significantly lower in prostate cancer patients compared to BPH patients (p < 0.01).
• Plasma serotonin levels were also lower in prostate cancer patients (p < 0.001), though within normal ranges.
• Intraplatelet beta-TG and PF4 levels were similar between the two patient groups.
• Beta-TG levels were significantly elevated in both patient groups compared to healthy individuals.

Conclusions:

• Platelet serotonin levels differ significantly between advanced prostate cancer patients and BPH patients.
• Platelet serotonin may serve as a valuable index for assessing platelet activation in prostate cancer.
• While platelet aggregation and certain proteins showed similarities, serotonin levels highlight a distinct platelet characteristic in prostate cancer.